Aging Blunts Non-Spike T Cell Defenses After COVID Vaccines and Breakthrough Infection

Older adults who have recovered from COVID-19 mount significantly weaker CD4+ T cell responses to inactivated SARS-CoV-2 vaccines than younger adults, and the deficit is concentrated in a surprising place: T cells that recognize parts of the virus other than the spike protein. That is the central finding of a longitudinal immunophenotyping study published in the Journal of Translational Medicine, which tracked immune responses in recovered individuals as they received inactivated vaccines and later experienced Omicron BA.5.2 or BF.7 breakthrough infections. The results help explain why aging compromises protection against reinfection and severe disease even in people with prior exposure to the virus, and they point toward vaccine strategies that may need to be tailored specifically for older immune systems.

The research team, led by Xing Fan, Jiahe Tian, Bo Zhang and senior authors Chao Zhang, Fu-Sheng Wang and Lei Huang of the Fifth Medical Center of Chinese PLA General Hospital and collaborating institutions in Beijing, Wuhan, Nanning and Hefei, focused on CD4+ T cells, the helper arm of adaptive immunity that orchestrates antiviral responses, supports antibody production and recruits other immune cells to sites of infection. While much vaccine research has centered on neutralizing antibodies directed against the viral spike protein, CD4+ T cells recognize a broader repertoire of viral antigens, including proteins such as nucleocapsid and membrane that are collectively termed non-spike targets. These non-spike-specific responses are thought to contribute to viral clearance and to cross-protection against variants whose spike mutations allow antibody escape.

To measure these responses with precision, the investigators used activation-induced marker assays, a flow cytometry-based technique in which peripheral blood mononuclear cells are stimulated with overlapping peptide pools covering spike or non-spike viral proteins. T cells that genuinely recognize the antigen respond within hours by expressing surface markers such as CD69 and CD154, allowing researchers to quantify the frequency of antigen-specific cells and to classify them into functional subsets. In parallel, the team measured cytokine secretion into culture supernatants, providing a readout of the inflammatory and antiviral signaling capacity of the responding cells. The longitudinal design followed participants across four key time points: before vaccination, after vaccination, before Omicron breakthrough infection and after that infection.

The comparison between younger adults aged 18 to 59 years and older adults aged 60 and above revealed a striking asymmetry. Younger recovered individuals showed robust CD4+ T cell activation following vaccination, with strong expansion of both spike-specific and non-spike-specific responses. Older adults, by contrast, exhibited attenuated responses overall, but the deficit was most pronounced in the non-spike compartment. Specifically, the frequency of Th1 cells among non-spike-specific CD4+ T cells was reduced in the older group. Th1 cells are the subset specialized for antiviral defense, characterized by their production of interferon-gamma, a cytokine that enhances viral antigen presentation, activates macrophages and supports cytotoxic lymphocyte function. A thinner Th1 layer against non-spike antigens means that a substantial portion of the viral proteome is met with a weaker cellular sentinel system in older vaccinees.

The memory phenotype of the responding cells also differed by age. Older adults carried a higher proportion of central memory cells among their antigen-specific CD4+ T cell populations. Central memory cells reside in lymphoid tissues and possess strong proliferative potential but slower effector function, whereas effector memory cells circulate in peripheral tissues and can act immediately upon antigen encounter. A memory pool skewed toward central memory may therefore provide a reserve of cells capable of expansion but a diminished first line of rapid effector defense at mucosal and tissue sites where SARS-CoV-2 initially replicates. This phenotypic shift adds a qualitative dimension to the age-related impairment, suggesting that it is not merely the quantity of responding cells but their differentiation state and tissue readiness that changes with age.

Functional output told a consistent story. When peripheral blood mononuclear cells from older participants were stimulated with non-spike peptide pools, they produced lower amounts of interferon-gamma than cells from younger participants. At the same time, they secreted higher levels of inflammatory cytokines including interleukin-10, interleukin-1 beta and interleukin-8. This combination is notable because it pairs a deficit in protective antiviral signaling with an excess of inflammatory output, a pattern consistent with the chronic low-grade inflammation of aging, sometimes called inflammaging. Interleukin-1 beta and interleukin-8 are associated with neutrophil recruitment and tissue inflammation, while interleukin-10 is an immunosuppressive cytokine that can dampen Th1 responses. Together, these shifts suggest that in older adults the response to vaccination is not simply weaker but qualitatively misdirected, favoring inflammation and regulation over targeted antiviral effector function.

A critical question was whether natural exposure to the Omicron variant could compensate for these vaccine-induced deficits. The answer, according to the study, was no. After participants experienced breakthrough infection with Omicron BA.5.2 or BF.7, the age-associated impairments persisted. Older adults showed compromised CD4+ T cell recall responses and a blunted expansion of non-spike-specific Th1 cells compared with younger individuals undergoing the same infection. Breakthrough infection effectively acts as a natural booster dose, re-exposing the immune system to the full viral proteome rather than only the spike antigen contained in the vaccine. The fact that older immune systems failed to expand their non-spike Th1 compartment even after this full-antigen encounter indicates a durable, intrinsic limitation rather than a transient gap in antigen exposure.

The implications for vaccine design are significant. Inactivated virus vaccines, which present the whole viral proteome to the immune system, were expected to elicit broad T cell recognition across spike and non-spike targets. The new data show that this breadth is achieved in younger adults but selectively lost in the non-spike Th1 compartment of older ones. Because Omicron variants carry numerous spike mutations that erode antibody neutralization, non-spike-specific T cell immunity has been proposed as a correlate of protection against severe disease that is more variant-resilient. If older adults cannot generate or recall these responses efficiently, they may remain vulnerable to severe outcomes despite vaccination, prior infection or both. The authors argue that their findings underscore the need for age-tailored vaccine strategies, which could include adjuvants that skew responses toward Th1 differentiation, higher antigen doses, alternative delivery platforms or booster formulations specifically designed to strengthen cellular immunity in older populations.

The study also contributes methodologically to a field that has often relied on antibody titers as the primary measure of vaccine success. By applying activation-induced marker assays longitudinally and dissecting T helper subsets, memory phenotypes and cytokine profiles, the researchers provide a template for evaluating cellular immunity with the granularity that correlates increasingly appears to demand. Their work was approved by the ethics committee of the Fifth Medical Center of Chinese PLA General Hospital, with written informed consent from all participants, and was funded by the National Key Research and Development Program of China, the National Natural Science Foundation of China and the Beijing Nova Program.

As populations age and SARS-CoV-2 continues to circulate and evolve, understanding precisely where immunity fails in older adults becomes a central task for vaccinology. This study localizes that failure with unusual clarity: not in the recognition of spike, and not in the raw presence of memory cells, but in the magnitude and functional polarization of Th1 responses against non-spike antigens, a defect that withstands both vaccination and natural reinfection. Closing that gap, whether through redesigned vaccines, targeted adjuvants or booster schedules calibrated to immune aging, may prove essential to extending the durable protection that younger immune systems achieve almost automatically.

Subject of Research: Age-related impairment of non-spike-specific Th1 CD4+ T cell responses to inactivated SARS-CoV-2 vaccination and Omicron breakthrough infection in recovered older adults

Article Title: Impaired non-spike-specific Th1 CD4+ T cell responses to inactivated SARS-CoV-2 vaccines and Omicron breakthrough infection in older individuals who had recovered from COVID-19

Article References: Fan, X., Tian, J., Zhang, B., Wang, J., Guo, Q., Guo, N., Li, X., Wang, G., Zhou, M.-J., Song, J.-W., Song, L., Mo, Q., Ni, W., Li, X., Zhou, L., Xu, X., Zhang, C., Wang, F.-S., & Huang, L. (2026). Impaired non-spike-specific Th1 CD4+ T cell responses to inactivated SARS-CoV-2 vaccines and Omicron breakthrough infection in older individuals who had recovered from COVID-19. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09062-5

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09062-5

Keywords: SARS-CoV-2, COVID-19, CD4+ T cells, Th1 cells, inactivated vaccines, Omicron breakthrough infection, aging, immunosenescence, inflammaging, T cell memory, interferon-gamma, vaccine strategy